NAD+

Scientific Overview

NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a central redox coenzyme. Research on NAD+ itself includes human infusion and metabolome studies, as well as broader NAD pharmacology reviews. Precursor strategies (e.g., nicotinamide riboside, NMN) are related but are not the same material as NAD+.

Mechanism focus

NAD+ supports sirtuin and PARP enzymatic activity and cellular redox balance. Direct NAD+ exposure studies document plasma and urine metabolome changes during infusion; precursor routes raise the NAD+ pool through biosynthetic pathways.

Research Use Cases

• NAD+ metabolome quantification
• Direct NAD+ infusion / exposure research
• Aging and senescence pathway research
• Skeletal-muscle bioenergetics studies

Use-Case Study Notations

• Case-study notation: a human pilot study documented plasma and urine NAD+ metabolome changes during a 6-hour intravenous NAD+ infusion.
• Case-study notation: reviews summarize research on direct NAD+ and precursor approaches.
• NAD+ itself differs from peptide APIs—handle analytical methods accordingly.

Selected Studies

1. 01 A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+PubMed 31572171
2. 02 Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world settingPubMed 41704678
3. 03 Clinical Evidence for Targeting NAD TherapeuticallyPubMed 32942582
4. 04 Roles of NAD+ in Health and AgingPubMed 37848251
5. 05 NAD+ therapy in age-related degenerative disorders: a benefit/risk analysisPubMed 31917996

Related compounds

KPV · Glutathione